secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-04-21T23:59:59+00:00
Accession:  0001140361-23-019505
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma terminates CEO Mina Sooch, appoints Rick Rodgers as interim CEO
-------------------------------------------------------------------------------

- On April 19, 2023, terminated CEO Mina Sooch; Richard Rodgers appointed interim President & CEO.
- Rodgers receives $40,000 monthly salary and 50,000 RSUs vesting in 12 months.
- Rodgers resigned from Audit and Compensation Committees; Gallagher and Manuso filled vacancies.
- Interim CEO to focus on APX3330 Phase 3 path and Nyxol NDA with PDUFA in September 2023.
- Company retained executive search firm to identify a permanent CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/brhc20051717_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-019505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer